Kinnate Biopharma Stock Price To Book
| KNTEDelisted Stock | USD 2.96 0.27 8.36% |
Kinnate Biopharma fundamentals help investors to digest information that contributes to Kinnate Biopharma's financial success or failures. It also enables traders to predict the movement of Kinnate Stock. The fundamental analysis module provides a way to measure Kinnate Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Kinnate Biopharma stock.
Kinnate |
Kinnate Biopharma Company Price To Book Analysis
Kinnate Biopharma's Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Current Kinnate Biopharma Price To Book | 0.79 X |
Most of Kinnate Biopharma's fundamental indicators, such as Price To Book, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Kinnate Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
CompetitionBased on the latest financial disclosure, Kinnate Biopharma has a Price To Book of 0.7855 times. This is 96.94% lower than that of the Biotechnology sector and 87.0% lower than that of the Health Care industry. The price to book for all United States stocks is 91.74% higher than that of the company.
Kinnate Price To Book Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Kinnate Biopharma's direct or indirect competition against its Price To Book to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Kinnate Biopharma could also be used in its relative valuation, which is a method of valuing Kinnate Biopharma by comparing valuation metrics of similar companies.Kinnate Biopharma is currently under evaluation in price to book category among its peers.
Kinnate Fundamentals
| Return On Equity | -0.56 | |||
| Return On Asset | -0.34 | |||
| Current Valuation | (25.71 M) | |||
| Shares Outstanding | 47.17 M | |||
| Shares Owned By Insiders | 0.15 % | |||
| Shares Owned By Institutions | 82.58 % | |||
| Number Of Shares Shorted | 465.63 K | |||
| Price To Book | 0.79 X | |||
| EBITDA | (118.21 M) | |||
| Net Income | (112.65 M) | |||
| Cash And Equivalents | 262.42 M | |||
| Cash Per Share | 5.94 X | |||
| Total Debt | 3.17 M | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 23.30 X | |||
| Book Value Per Share | 3.66 X | |||
| Cash Flow From Operations | (100.04 M) | |||
| Short Ratio | 0.96 X | |||
| Earnings Per Share | (2.78) X | |||
| Target Price | 2.36 | |||
| Number Of Employees | 84 | |||
| Beta | 1.34 | |||
| Market Capitalization | 124.99 M | |||
| Total Asset | 173.6 M | |||
| Retained Earnings | (372.01 M) | |||
| Working Capital | 146.18 M | |||
| Z Score | 19.38 | |||
| Net Asset | 173.6 M |
About Kinnate Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Kinnate Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kinnate Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kinnate Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Other Consideration for investing in Kinnate Stock
If you are still planning to invest in Kinnate Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kinnate Biopharma's history and understand the potential risks before investing.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |